New Body Blow For Aducanumab As Japan Asks For More Data
Executive Summary
Request for additional data after a surprise review committee meeting sets back approval in potentially large market, adding to Biogen and Eisai’s woes following the recent EU negative opinion and poor performance and price cut in the US.